Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination

5 October 2026 · By · Wire by Fusion42

Published

5 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 5 October 2026 · Fusion42 review

Trethera Corporation received FDA Fast Track designation for TRE-515, a dCK inhibitor, in combination with KRAS G12C inhibitors to treat previously treated KRAS G12C-mutated non-small cell lung cancer, addressing resistance to current KRAS G12C inhibitors.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now focus on KRAS G12C-resistant lung cancer patients using a novel dCK inhibitor combo that may bypass current treatment failures. Trethera's FDA Fast Track opens a path to quicker clinical adoption and competitive positioning in NSCLC treatment.

◆ Coverage

1 source · 5 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-fast-trackkras-g12clung-cancerdck-inhibitortrethera